133 related articles for article (PubMed ID: 24952352)
1. Development of antileishmanial lipid nanocomplexes.
Pham TT; Gueutin C; Cheron M; Abreu S; Chaminade P; Loiseau PM; Barratt G
Biochimie; 2014 Dec; 107 Pt A():143-53. PubMed ID: 24952352
[TBL] [Abstract][Full Text] [Related]
2. Interactions of antileishmanial drugs with monolayers of lipids used in the development of amphotericin B-miltefosine-loaded nanocochleates.
Pham TT; Barratt G; Michel JP; Loiseau PM; Saint-Pierre-Chazalet M
Colloids Surf B Biointerfaces; 2013 Jun; 106():224-33. PubMed ID: 23434716
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical characterization of molecular assemblies of miltefosine and amphotericin B.
Ménez C; Legrand P; Rosilio V; Lesieur S; Barratt G
Mol Pharm; 2007; 4(2):281-8. PubMed ID: 17397240
[TBL] [Abstract][Full Text] [Related]
4. Hexadecylphosphocholine (Miltefosine) stabilized chitosan modified Ampholipospheres as prototype co-delivery vehicle for enhanced killing of L. donovani.
Tripathi P; Jaiswal AK; Dube A; Mishra PR
Int J Biol Macromol; 2017 Dec; 105(Pt 1):625-637. PubMed ID: 28716750
[TBL] [Abstract][Full Text] [Related]
5. Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro.
Ménez C; Buyse M; Besnard M; Farinotti R; Loiseau PM; Barratt G
Antimicrob Agents Chemother; 2006 Nov; 50(11):3793-800. PubMed ID: 16966395
[TBL] [Abstract][Full Text] [Related]
6. Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis.
Parvez S; Yadagiri G; Gedda MR; Singh A; Singh OP; Verma A; Sundar S; Mudavath SL
Sci Rep; 2020 Jul; 10(1):12243. PubMed ID: 32699361
[TBL] [Abstract][Full Text] [Related]
7. Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes.
Dar MJ; Khalid S; McElroy CA; Satoskar AR; Khan GM
Int J Pharm; 2020 Jan; 573():118900. PubMed ID: 31765786
[TBL] [Abstract][Full Text] [Related]
8. Nanoemulsions loaded with amphotericin B: a new approach for the treatment of leishmaniasis.
Caldeira LR; Fernandes FR; Costa DF; Frézard F; Afonso LC; Ferreira LA
Eur J Pharm Sci; 2015 Apr; 70():125-31. PubMed ID: 25660615
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, biodistribution, and activity of Amphotericin B-loaded nanocochleates on the Leishmania donovani murine visceral leishmaniasis model.
Lipa Castro A; Pomel S; Cailleau C; Fournier N; Dennemont I; Loiseau PM; Barratt G
Int J Pharm; 2022 Aug; 624():121985. PubMed ID: 35820519
[TBL] [Abstract][Full Text] [Related]
10. Strategies for the design of orally bioavailable antileishmanial treatments.
Pham TT; Loiseau PM; Barratt G
Int J Pharm; 2013 Sep; 454(1):539-52. PubMed ID: 23871737
[TBL] [Abstract][Full Text] [Related]
11. Chitosan-assisted immunotherapy for intervention of experimental leishmaniasis via amphotericin B-loaded solid lipid nanoparticles.
Jain V; Gupta A; Pawar VK; Asthana S; Jaiswal AK; Dube A; Chourasia MK
Appl Biochem Biotechnol; 2014 Oct; 174(4):1309-1330. PubMed ID: 25106894
[TBL] [Abstract][Full Text] [Related]
12. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
Wasan KM; Wasan EK; Gershkovich P; Zhu X; Tidwell RR; Werbovetz KA; Clement JG; Thornton SJ
J Infect Dis; 2009 Aug; 200(3):357-60. PubMed ID: 19545212
[TBL] [Abstract][Full Text] [Related]
13. Development of targeted 1,2-diacyl-sn-glycero-3-phospho-l-serine-coated gelatin nanoparticles loaded with amphotericin B for improved in vitro and in vivo effect in leishmaniasis.
Khatik R; Dwivedi P; Khare P; Kansal S; Dube A; Mishra PR; Dwivedi AK
Expert Opin Drug Deliv; 2014 May; 11(5):633-46. PubMed ID: 24606222
[TBL] [Abstract][Full Text] [Related]
14. Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine.
Carregal VM; Lanza JS; Souza DM; Islam A; Demicheli C; Fujiwara RT; Rivas L; Frézard F
Parasitol Res; 2019 Oct; 118(10):3077-3084. PubMed ID: 31401656
[TBL] [Abstract][Full Text] [Related]
15. Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: active ingredient and mediator of drug release.
Lindner LH; Hossann M; Vogeser M; Teichert N; Wachholz K; Eibl H; Hiddemann W; Issels RD
J Control Release; 2008 Jan; 125(2):112-20. PubMed ID: 18022271
[TBL] [Abstract][Full Text] [Related]
16. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
Croft SL; Engel J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
[TBL] [Abstract][Full Text] [Related]
17. Visceral leishmaniasis in children: a review.
Palumbo E
Minerva Pediatr; 2010 Aug; 62(4):389-95. PubMed ID: 20940672
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting.
Gupta S; Vyas SP
J Drug Target; 2007 Apr; 15(3):206-17. PubMed ID: 17454358
[TBL] [Abstract][Full Text] [Related]
19. A new nanoemulsion formulation improves antileishmanial activity and reduces toxicity of amphotericin B.
Santos DCMD; de Souza MLS; Teixeira EM; Alves LL; Vilela JMC; Andrade M; Carvalho MDG; Fernandes AP; Ferreira LAM; Aguiar MMG
J Drug Target; 2018 Apr; 26(4):357-364. PubMed ID: 29041824
[TBL] [Abstract][Full Text] [Related]
20. Liposomal formulations in the pharmacological treatment of leishmaniasis: a review.
Ortega V; Giorgio S; de Paula E
J Liposome Res; 2017 Sep; 27(3):234-248. PubMed ID: 28874072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
